Northern Trust Corp Makes New $2.36 Million Investment in Upstream Bio, Inc. (NASDAQ:UPB)

Northern Trust Corp acquired a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 143,721 shares of the company's stock, valued at approximately $2,363,000. Northern Trust Corp owned 0.27% of Upstream Bio at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC acquired a new position in shares of Upstream Bio in the 4th quarter valued at $117,977,000. Decheng Capital LLC acquired a new position in shares of Upstream Bio in the 4th quarter valued at $54,010,000. Bain Capital Life Sciences Investors LLC acquired a new position in shares of Upstream Bio in the 4th quarter valued at $37,735,000. Wellington Management Group LLP acquired a new position in shares of Upstream Bio in the 4th quarter valued at $25,632,000. Finally, Alliancebernstein L.P. acquired a new position in shares of Upstream Bio in the 4th quarter valued at $18,270,000.

Upstream Bio Stock Performance

Shares of UPB traded up $0.33 during trading hours on Thursday, hitting $9.55. The stock had a trading volume of 186,748 shares, compared to its average volume of 329,060. The firm has a 50-day moving average price of $8.11 and a 200 day moving average price of $12.10. Upstream Bio, Inc. has a fifty-two week low of $5.14 and a fifty-two week high of $29.46.

Upstream Bio (NASDAQ:UPB - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.71 million. Equities research analysts anticipate that Upstream Bio, Inc. will post -4.3 earnings per share for the current year.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.